ARV7-high and PSA-positive CR-PCa patients treated with abiraterone had a median overall survival of 21.3 months, while ARV7-low and PSA-positive patients had overall survival of 34.4 months and PSA-negative patients had overall survival of 43.2 months [87]. Here, PROS1 is linked to posterior cortical atrophy.